Andrew D. Kelly

机构：Boston Foundation, Foundation Medicine (United States) · ORCID：0000-0002-5338-7689

发表论文 60 篇 · 总被引 980 次 · h-index 13

代表论文

• TET1-Mediated Hypomethylation Activates Oncogenic Signaling in Triple-Negative Breast Cancer (2018 · Cancer Research · 被引 176)
• The promise of epigenetic therapy: reprogramming the cancer epigenome (2017 · Current Opinion in Genetics & Development · 被引 161)
• MicroRNA paraffin-based studies in osteosarcoma reveal reproducible independent prognostic profiles at 14q32 (2013 · Genome Medicine · 被引 120)
• Epigenetics and Precision Oncology (2017 · The Cancer Journal · 被引 95)
• Metabolomic Profiling from Formalin-Fixed, Paraffin-Embedded Tumor Tissue Using Targeted LC/MS/MS: Application in Sarcoma (2011 · PLoS ONE · 被引 78)
• An imprinted non-coding genomic cluster at 14q32 defines clinically relevant molecular subtypes in osteosarcoma across multiple independent datasets (2017 · Journal of Hematology & Oncology · 被引 42)